Literature DB >> 20238246

HCC in older patients.

Brian I Carr1, Petr Pancoska, Robert A Branch.   

Abstract

BACKGROUND: Hepatocellular carcinoma (HCC) is a heterogeneous disease, with many poorly-defined prognostic patient subsets. Identification of discrete subsets will aid rational patient and treatment selection.
METHODS: A database with 778 biopsy-proven, unresectable and untransplantable HCC patients who were followed from diagnosis till death was interrogated. Using a moving average algorithm, patients were ordered by survival and then survival cohorts were analyzed according to standard liver function and CT characteristic parameters.
RESULTS: We found characteristic age clustering groupings by survival. In the older age patients, two survival sub-groups were identified, with 45-80 days in one and 330-1,250 days survival in the other group. The longer surviving group had the lowest serum bilirubin and AFP levels and the lowest tumor mass. Remarkably, the trends for both AFP and bilirubin were similar, suggesting that they were not independent variables. This idea was supported by the similar correlation of typical AFP with GGTP, ALKP and SGOT levels.
CONCLUSIONS: A large HCC cohort showed significant age clustering characteristics for survival, especially in older patients. AFP, bilirubin and age were found to be inter-related factors for HCC severity and survival.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20238246     DOI: 10.1007/s10620-010-1177-6

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  13 in total

1.  Prognostic accuracy of 12 liver staging systems in patients with unresectable hepatocellular carcinoma treated with transarterial chemoembolization.

Authors:  Christos S Georgiades; Eleni Liapi; Constantine Frangakis; Ju-un Park; Hyung Woo Kim; Kelvin Hong; Jean-Francois H Geschwind
Journal:  J Vasc Interv Radiol       Date:  2006-10       Impact factor: 3.464

Review 2.  Clinical features and prognosis of hepatocellular carcinoma with reference to serum alpha-fetoprotein levels. Analysis of 606 patients.

Authors:  F Nomura; K Ohnishi; Y Tanabe
Journal:  Cancer       Date:  1989-10-15       Impact factor: 6.860

3.  A new prognostic system for hepatocellular carcinoma: a retrospective study of 435 patients: the Cancer of the Liver Italian Program (CLIP) investigators.

Authors: 
Journal:  Hepatology       Date:  1998-09       Impact factor: 17.425

4.  Prognosis of hepatocellular carcinoma: the BCLC staging classification.

Authors:  J M Llovet; C Brú; J Bruix
Journal:  Semin Liver Dis       Date:  1999       Impact factor: 6.115

5.  A modified TNM-based Japan Integrated Score combined with AFP level may serve as a better staging system for early-stage predominant hepatocellular carcinoma patients.

Authors:  Y-H Yen; C-S Changchien; J-H Wang; K-M Kee; C-H Hung; T-H Hu; C-M Lee; C-Y Lin; C-C Wang; T-Y Chen; Y-J Huang; S-N Lu
Journal:  Dig Liver Dis       Date:  2009-01-29       Impact factor: 4.088

6.  Serum alpha-fetoprotein level per tumor volume reflects prognosis in patients with hepatocellular carcinoma after curative hepatectomy.

Authors:  Tadashi Furihata; Tokihiko Sawada; Junji Kita; Yukihiro Iso; Masato Kato; Kyu Rokkaku; Mitsugi Shimoda; Keiichi Kubota
Journal:  Hepatogastroenterology       Date:  2008 Sep-Oct

7.  Comparison of seven prognostic staging systems in patients who undergo hepatectomy for hepatocellular carcinoma.

Authors:  Kazuhiro Kondo; Kazuo Chijiiwa; Motoaki Nagano; Masahide Hiyoshi; Masahiro Kai; Naoki Maehara; Jiro Ohuchida; Hiroyuki Nakao; Yoshiaki Ohkuwa
Journal:  Hepatogastroenterology       Date:  2007 Jul-Aug

8.  High alpha-fetoprotein level correlates with high stage, early recurrence and poor prognosis of hepatocellular carcinoma: significance of hepatitis virus infection, age, p53 and beta-catenin mutations.

Authors:  Shian-Yang Peng; Wei J Chen; Po-Lin Lai; Yun-Ming Jeng; Jin-Chuan Sheu; Hey-Chi Hsu
Journal:  Int J Cancer       Date:  2004-10-20       Impact factor: 7.396

9.  Staging of hepatocellular carcinoma: assessment of the Japanese TNM and AJCC/UICC TNM systems in a cohort of 13,772 patients in Japan.

Authors:  Masami Minagawa; Iwao Ikai; Yutaka Matsuyama; Yoshio Yamaoka; Masatoshi Makuuchi
Journal:  Ann Surg       Date:  2007-06       Impact factor: 12.969

10.  A simple prognostic scoring system for patients with unresectable hepatocellular carcinoma treated by chemo-embolization.

Authors:  Igor Dvorchik; Brian I Carr
Journal:  Cancer Detect Prev       Date:  2007-04-09
View more
  5 in total

1.  Identification of two clinical hepatocellular carcinoma patient phenotypes from results of standard screening parameters.

Authors:  Petr Pancoska; Brian I Carr; Edoardo G Giannini; Fabio Farinati; Francesca Ciccarese; Gian Ludovico Rapaccini; Maria Di Marco; Luisa Benvegnù; Marco Zoli; Franco Borzio; Eugenio Caturelli; Maria Chiaramonte; Franco Trevisani
Journal:  Semin Oncol       Date:  2014-04-24       Impact factor: 4.929

2.  Small HCCs identified by screening.

Authors:  Petr Pancoska; Massimo De Giorgio; Stefano Fagiuoli; Brian I Carr
Journal:  Dig Dis Sci       Date:  2011-04-05       Impact factor: 3.199

3.  Phenotypic Categorization and Profiles of Small and Large Hepatocellular Carcinomas.

Authors:  Petr Pancoska; Sheng-Nan Lu; Brian I Carr
Journal:  J Gastrointest Dig Syst       Date:  2013-03-02

4.  Macro- and micro-environmental factors in clinical hepatocellular cancer.

Authors:  Petr Pancoska; Brian I Carr
Journal:  Semin Oncol       Date:  2014-03-07       Impact factor: 4.929

5.  Association between socioeconomic status and survival in patients with hepatocellular carcinoma.

Authors:  Yongshun Zheng; Xun Zhang; Jinsen Lu; Shuchen Liu; Yeben Qian
Journal:  Cancer Med       Date:  2021-08-20       Impact factor: 4.452

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.